1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Chemotherapy-Induced Neutropenia - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2019-2024) and Forecast (2025-2035)
4.4 Market Overview (2019-2024) and Forecast (2025-2035)
4.5 Competitive Intelligence
5 Chemotherapy-Induced Neutropenia - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Chemotherapy-Induced Neutropenia - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2019-2024)
7.2.2 Epidemiology Forecast (2025-2035)
7.2.3 Epidemiology by Age (2019-2035)
7.2.4 Epidemiology by Gender (2019-2035)
7.2.5 Diagnosed Cases (2019-2035)
7.2.6 Patient Pool/Treated Cases (2019-2035)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2019-2024)
7.3.2 Epidemiology Forecast (2025-2035)
7.3.3 Epidemiology by Age (2019-2035)
7.3.4 Epidemiology by Gender (2019-2035)
7.3.5 Diagnosed Cases (2019-2035)
7.3.6 Patient Pool/Treated Cases (2019-2035)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2019-2024)
7.4.2 Epidemiology Forecast (2025-2035)
7.4.3 Epidemiology by Age (2019-2035)
7.4.4 Epidemiology by Gender (2019-2035)
7.4.5 Diagnosed Cases (2019-2035)
7.4.6 Patient Pool/Treated Cases (2019-2035)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2019-2024)
7.5.2 Epidemiology Forecast (2025-2035)
7.5.3 Epidemiology by Age (2019-2035)
7.5.4 Epidemiology by Gender (2019-2035)
7.5.5 Diagnosed Cases (2019-2035)
7.5.6 Patient Pool/Treated Cases (2019-2035)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2019-2024)
7.6.2 Epidemiology Forecast (2025-2035)
7.6.3 Epidemiology by Age (2019-2035)
7.6.4 Epidemiology by Gender (2019-2035)
7.6.5 Diagnosed Cases (2019-2035)
7.6.6 Patient Pool/Treated Cases (2019-2035)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2019-2024)
7.7.2 Epidemiology Forecast (2025-2035)
7.7.3 Epidemiology by Age (2019-2035)
7.7.4 Epidemiology by Gender (2019-2035)
7.7.5 Diagnosed Cases (2019-2035)
7.7.6 Patient Pool/Treated Cases (2019-2035)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2019-2024)
7.8.2 Epidemiology Forecast (2025-2035)
7.8.3 Epidemiology by Age (2019-2035)
7.8.4 Epidemiology by Gender (2019-2035)
7.8.5 Diagnosed Cases (2019-2035)
7.8.6 Patient Pool/Treated Cases (2019-2035)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2019-2024)
7.9.2 Epidemiology Forecast (2025-2035)
7.9.3 Epidemiology by Age (2019-2035)
7.9.4 Epidemiology by Gender (2019-2035)
7.9.5 Diagnosed Cases (2019-2035)
7.9.6 Patient Pool/Treated Cases (2019-2035)
8 Chemotherapy-Induced Neutropenia - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Chemotherapy-Induced Neutropenia - Unmet Needs
10 Chemotherapy-Induced Neutropenia - Key Endpoints of Treatment
11 Chemotherapy-Induced Neutropenia - Marketed Products
11.1 List of Chemotherapy-Induced Neutropenia Marketed Drugs Across the Top 7 Markets
11.1.1 Neupogen (Filgrastim) – Amgen Inc.
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rolvedon (Eflapegrastim-xnst) – Spectrum Pharmaceuticals, Inc.
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Neulasta (Pegfilgrastim) – Amgen Inc.
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Udenyca (Pegfilgrastim-cbqv) – Coherus BioSciences, Inc.
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Fylnetra (Pegfilfrastim-pbbk) – Amneal Pharmaceuticals LLC.
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 Chemotherapy-Induced Neutropenia - Pipeline Drugs
12.1 List of Chemotherapy-Induced Neutropenia Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. Chemotherapy-Induced Neutropenia - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Chemotherapy-Induced Neutropenia – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Chemotherapy-Induced Neutropenia - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chemotherapy-Induced Neutropenia - Market Size
15.2.1.1 Market Size (2019-2024)
15.2.1.2 Market Forecast (2025-2035)
15.2.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2019-2024)
15.2.2.2 Market Forecast by Therapies (2025-2035)
15.3 Market Scenario - United States
15.3.1 Chemotherapy-Induced Neutropenia - Market Size
15.3.1.1 Market Size (2019-2024)
15.3.1.2 Market Forecast (2025-2035)
15.3.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2019-2024)
15.3.2.2 Market Forecast by Therapies (2025-2035)
15.3.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chemotherapy-Induced Neutropenia - Market Size
15.4.1.1 Market Size (2019-2024)
15.4.1.2 Market Forecast (2025-2035)
15.4.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2019-2024)
15.4.2.2 Market Forecast by Therapies (2025-2035)
15.4.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chemotherapy-Induced Neutropenia - Market Size
15.5.1.1 Market Size (2019-2024)
15.5.1.2 Market Forecast (2025-2035)
15.5.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2019-2024)
15.5.2.2 Market Forecast by Therapies (2025-2035)
15.5.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chemotherapy-Induced Neutropenia - Market Size
15.6.1.1 Market Size (2019-2024)
15.6.1.2 Market Forecast (2025-2035)
15.6.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2019-2024)
15.6.2.2 Market Forecast by Therapies (2025-2035)
15.6.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chemotherapy-Induced Neutropenia - Market Size
15.7.1.1 Market Size (2019-2024)
15.7.1.2 Market Forecast (2025-2035)
15.7.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2019-2024)
15.7.2.2 Market Forecast by Therapies (2025-2035)
15.7.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chemotherapy-Induced Neutropenia - Market Size
15.8.1.1 Market Size (2019-2024)
15.8.1.2 Market Forecast (2025-2035)
15.8.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2019-2024)
15.8.2.2 Market Forecast by Therapies (2025-2035)
15.8.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chemotherapy-Induced Neutropenia - Market Size
15.9.1.1 Market Size (2019-2024)
15.9.1.2 Market Forecast (2025-2035)
15.9.2 Chemotherapy-Induced Neutropenia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2019-2024)
15.9.2.2 Market Forecast by Therapies (2025-2035)
15.9.3 Chemotherapy-Induced Neutropenia - Access and Reimbursement Overview
16 Chemotherapy-Induced Neutropenia - Recent Events and Inputs From Key Opinion Leaders
17 Chemotherapy-Induced Neutropenia Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Chemotherapy-Induced Neutropenia Market – Strategic Recommendations
19 Appendix